ARCHIVES

Phase III Study: Rituxan Improved PFS By 79% In Advanced Follicular Lymphoma

This article is from The Cancer Letter archive.

Vol. 33 No. 12 | December 31, 2010

Download PDF Visit The Full Archive

Related Articles

Proposed Surveillance Model Aims To Reduce Post-Treatment Pain

April 27, 2012

To Improve Clinical Trials Participation, Groups Plan An Awareness Campaign.

October 13, 2000

FDA Approves Folotyn For Peripheral T-Cell Lymphoma

September 25, 2009

Senate approves NIH funding bill. NCI awards $25 million to eight institutions for patient navigator programs; $35 million awarded for nanotechnology partnerships.

October 28, 2005

Community Assn. Meeting Includes Provocative Workshops

January 31, 1975

Erbitux Improves Survival In Advanced Colorectal Cancer

November 30, 2007